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Abstract
Background: Schizophrenia is thought to be a neurodevelopmental disorder with pathophysiological processes
beginning in the brain prior to the emergence of clinical symptoms. Recent evidence from neuroimaging studies
using techniques such as diffusion tensor imaging has identified white matter abnormalities that are suggestive of
disrupted brain myelination and neuronal connectivity. Identifying whether such effects exist in individuals at high
risk for developing psychosis may help with prevention and early intervention strategies. In addition, there is
preliminary evidence for a role of lipid biology in the onset of psychosis, along with well-established evidence of its
role in myelination of white matter tracts. As such, this article synthesises the literature on polyunsaturated fatty
acids (PUFAs) in myelination and schizophrenia, hypothesizing that white matter abnormalities may potentially
mediate the relationship between PUFAs and schizophrenia.
Methods: Diffusion tensor imaging studies were identified through a systematic search of existing literature.
Studies examined white matter integrity in ultra-high risk (UHR) samples, as assessed using structured diagnostic
interviews. Data was extracted and summarised as a narrative review.
Results: Twelve studies met inclusion criteria, and findings identified reduced fractional anisotropy and higher
diffusivity. Although the exact location of abnormalities remains uncertain, fronto-temporal and fronto-limbic
connections, including the superior longitudinal and uncinate fasiculus, cingulum, and corpus callosum appear to
be implicated. Because of preliminary evidence suggesting lipid biology may be relevant for the onset of psychosis,
a discussion is provided of the role of polyunsaturated fatty acids (PUFAs) in myelination and risk for psychosis.
Conclusions: While the function of PUFAs in myelination is well-established, there is growing evidence of reduced
PUFA concentration in UHR samples, highlighting the need for research to examine the relationship between PUFA
and white matter integrity in high-risk samples and age-matched healthy controls. Such investigations will help to
better understand the pathophysiology of the disorder, and potentially assist in the development of novel
treatment and early intervention strategies.
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Background
Schizophrenia is often a chronic disorder, characterised
by delusions, hallucinations, blunted affect and cognitive
impairment [1, 2], which commonly presents during late
adolescence or early adulthood [3]. Though it has long
been postulated to be a disorder of neurodevelopment
with pathophysiological processes beginning in the brain
prior to the onset of clinical symptoms [1, 2], the advent
of neuroimaging techniques has been instrumental in
probing these neurobiological processes. While these
techniques have provided unique insights into various
aspects of brain morphometry and function, of particu-
lar relevance to psychosis is diffusion tensor imaging
(DTI) studies on white matter integrity in fibre tracts
connecting brain regions. We review this research within
samples at ultra-high risk (UHR) for psychosis, in order
to identify white matter abnormalities that may be impli-
cated in the development of the illness. There is also a
substantial body of evidence for lowered cell membrane
polyunsaturated fatty acids (PUFA) concentrations in
schizophrenia, which compose the myelin sheath
surrounding white-matter tracts. Therefore, we end the
review with a discussion about the role of PUFAs in
myelination and schizophrenia, hypothesizing that white
matter abnormalities may potentially mediate the rela-
tionship between PUFAs and schizophrenia. We also
highlight the need to examine these relationships in fur-
ther detail among UHR samples to better understand
the pathophysiology of the disorder, and potentially as-
sist in the development of novel treatment and early
intervention strategies.
DTI measures the diffusion of water molecules
through tissues, and provides a measure of net direction-
ality and magnitude (diffusivity). The net directionality
of diffusion, indexed by fractional anisotropy (FA), is the
most common index of white matter integrity. Lower FA
has been associated with reduced axonal caliber and
packing density, myelin pathology, as well as less coher-
ent fibres or crossing fibres within a voxel [4]. Mean dif-
fusivity (MD) is another frequently used index that
quantifies overall diffusion within a particular voxel, with
higher values suggestive of disrupted axonal integrity
[5]. Research on normative developmental patterns of
white matter integrity has identified significant increases
in FA and decreases in diffusivities during childhood and
adolescence across all the major fibre tracts [6]. While
most of these changes are complete by the end of ado-
lescence, some association tracts (i.e. inferior and super-
ior longitudinal and fronto-occipital fasciculi) continue
to develop during early adulthood [7]. It is particularly
important to consider these normative developmental
trajectories when interpreting white matter integrity in
UHR samples, given that most of these individuals are
adolescents.
White matter integrity in schizophrenia
DTI studies have provided extensive evidence for lowered
white matter integrity across the brain in schizophrenia,
including the uncinate fasiculus and fornix, fronto-
occipital fasiculus, arcuate fasiculus, anterior commissure,
cingulum bundle and corticospinal tract [for review, see
[8, 9]]. However, it is uncertain whether these white mat-
ter abnormalities are intrinsic to schizophrenia, given that
these studies are often confounded by multiple factors, in-
cluding chronicity of the illness, treatment with anti-
psychotic medication [10, 11], sex and age of participants
[12], and even heavy cigarette smoking [13].
Longitudinal research on individuals at UHR for
psychosis enables assessment prior to, during and fol-
lowing the onset of illness. These individuals represent a
‘clinical high-risk’ group, who present with sub-threshold
or brief psychotic symptoms, may have trait factors such
as a genetic risk for the disorder, and exhibit a signifi-
cant decline in functioning [14]. This prodromal phase
is associated with enhanced risk for development of
schizophrenia compared to the general population or to
those at genetic risk for the illness, with transition rates
ranging from 18 % after six months to 35 % after a ten
year period [15, 16]. Thus, by following these individuals
over time, it is possible to identify factors that may predict
transition to psychotic illnesses, as well as better under-
stand the neurobiological processes underlying this pro-
gression [17, 18], including white matter abnormalities
during transition to psychosis [19]. This information may
help identify early intervention and preventative measures
that may halt the progression from sub-threshold symp-
toms to fully-fledged illness. Below, we provide a systematic
review of DTI findings in individuals at UHR for psychosis.
Methods
We followed the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses’ (PRISMA) guidelines.
An electronic search was conducted in PubMed and
Medline, using the key words high risk, psychosis, diffu-
sion tensor imaging and white matter, to identify studies
published in this field to date (July 2015). Inclusion cri-
teria for the review were: i. employed DTI, ii. included
subjects at ultra high risk for psychosis, assessed using
structured diagnostic interviews (such as the Structured
Interview for Prodromal Syndromes [20] or the Compre-
hensive Assessment of At-Risk Mental States [21]), iii.
compared these participants to a healthy control group
on DTI measures, and iv. were written in English. The
reference lists of identified articles were also searched
for further relevant articles. Figure 1 summarizes the
search strategy used for selecting studies [identification,
screening, eligibility, inclusion process] in the present re-
view. We excluded studies that were classified as high
risk based only on familial risk alone. In total, 12 studies
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were identified that fit the above-mentioned criteria (See
Table 1 for details).
Results and discussion
DTI studies of individuals at ultra high risk for psychosis
Peters and colleagues [22] conducted the first DTI study
to investigate white matter abnormalities in a UHR sam-
ple, and failed to identify any differences in FA within a
priori white matter tracts using fibretracking (including
the uncinate and arcuate fasciculus, anterior and dorsal
cingulum, sub-divisions of the corpus callosum) between
10 male UHR subjects, 10 with recent-onset schizophre-
nia and 10 healthy controls. However, a subsequent
study on the same sample using whole brain voxel-wise
analysis identified significantly reduced FA in UHR pa-
tients compared to controls within the white matter of
the right superior frontal lobe and left middle frontal
lobe [23]. While those with schizophrenia were found to
have significantly reduced FA in the left frontal and
bilateral temporal and parietal regions compared to con-
trols, no significant differences were identified between
UHR and schizophrenia patients. Similarly, Epstein et al.
[24] found lowered FA in the bilateral corticospinal tract,
left inferior longitudinal fasciculus and left inferior
fronto-occipital fasciculus in UHR adolescents and those
with schizophrenia compared to healthy controls,
though no significant differences were identified between
the two groups. A recent study that investigated whole
brain differences in DTI measures also identified a trend
towards reduced FA in UHR [25]. Stronger effects were
identified in relation to MD, with significantly increased
levels [reflecting a reduction in white matter integrity]
present in the UHR group in the superior longitudinal
fasiculus, corona radiata and corpus callosum.
While the aforementioned studies have identified
white matter differences in a range of white matter fas-
ciculi, they did not examine transition to psychosis
within UHR samples. As mentioned earlier, while some
Fig. 1 PRISMA 2009 Flow Diagram
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Table 1 Diffusion tensor imaging studies on ultra-high risk samples
Reference Population UHR
assessment
DTI parametersa Technique Major Findings
Bloemen et al., [30] 27 UHR-N (18 M, mean age = 18.9),
10 UHR-P (8 M, mean age = 20.7),
10 HC (8 M, mean age = 22.7)
SIPS 3 T, EPI, 48 continuous
3 mm slices, 2x2x3mm
VBA, whole brain UHR-P vs. HC: ↓ FA in bilateral medial frontal lobes.
UHR-P vs. UHR-N: ↓ FA lateral to right putamen and
left superior temporal lobe,↑FA in left medial
temporal
lobe.
Positive PANSS negatively correlated with FA in left
medial temporal lobe in UHR-P group, and right
superior temporal lobe in total UHR group.
Carletti et a., [31] Baseline: 32 UHR (19 M, mean
age = 23.4), 14 EOS (14 M, mean
age = 25.9), 32 HC (27 M,
mean age = 25.9)
CAARMS 1.5 T, EPI, 60 contiguous 2.5 mm
axial slices, 1.875x1.875x2.5 mm
VBA, whole brain Baseline: FA was lowest in EOS, highest in HC and
intermediate in UHR group. Clusters comprised in
areas corresponding to CC, left ILF & SLF, left IFOF
and cortico-subcortical pathways.
Follow-up: 22 UHR (5 UHR-P, 17 UHR-N)
subjects (11 M, mean age = 26.6), 8 NC
(17 M, mean age = 29.6)
Longitudinal UHR-P vs. UHR-N: ↓ FA over time in left
frontal white matter, CC, SCR and SFOF. But no
significant within group change.
Bernard et al., [29] 26UHR (20 M, mean age = 18.5), 21 HC
(15 M, mean age = 17.77)
SIPS 3 T, EPI, GRAPPA parallel imaging
factor 2, 72 slices, 2x2x2mm
TBSS, ROI = thalamic-
hippocampal tract
UHR vs. HC: Significant group*time interaction.
Controls FA ↑ over 12 months, while UHR FA ↓ over
time (but no significant main effect of time).
Follow-up: 15UHR, 15 HC
Clemm von Hohenberg
et al., [25]
28 UHR (18 M, mean age = 20.6), 34 HC
(18 F, mean age = 20.4)
SOPS 3 T, EPI, 75 contiguous axial 2 mm
slices, 2x2x2mm
TBSS, whole brain UHR vs. HC: MD ↑ in several right hemisphere
clusters (most notably SLF, posterior corona radiata,
and CC). RD ↑ posterior parietal lobe.
Epstein et al. [24] 21 UHR (18 M, mean age = 16.1), 55 EOS
(31 M, mean age = 16.9), 55 HC (27 M,
mean age = 16.5), 31 cannabis use
(non-psychotic, 22 M, mean age = 17.6).
SIPS 3 T, EPI, 64 sagittal 2 mm slices,
2x2x2mm
Fiber tracking, ROIs = CB,
SLF, CST, ILF, IFOF, and UF
EOS and UHR vs. HC and cannabis: FA ↓ bilateral
CST
EOS and UHR vs. HC: FA ↓ left ILF and IFOF
Karlsgodt et al., [27] 36 UHR (27 M, mean age = 17.0), 25 HC
(12 M, mean age = 18.0)
SIPS 1.5 T, EPI, 75 contiguous 2 mm
AC-PC interleaved slices, 2x2x2mm
TBSS, ROIs = UF, AF, CB,
ILF, MTL, ATR
UHR vs. HC: FA ↓ SLF at baseline. Did not increase
FA with
age in MTL and ILF.
FA ↓ MTL and ILF at baseline predicted reductions
in functional outcomes in UHR.
Katagiri et al., [32] 16HC (8 M, mean age = 23.2), 11 UHR-
NN(3 M, mean age = 24.2), 23 UHR-NA
(6 M, mean age = 23.4), 7 UHR-P (1 M,
mean age = 20.7)
SIPS 1.5 T, EPI, 30 axial slices, 1.02 ×
1.02 × 5 mm
TBSS, whole brain for
baseline analyses,
followed by ROI (CC) for
longitudinal analyses
Baseline: UHR vs. HC: ↓ FA in CC. Result also present in
UHR-N vs. HC. Longitudinal: UHR-N improvements in
positive symptoms at follow-up, which correlated with
increased FA in the CC.
Follow-up: same groups as above
Mittal et al., [28] 33UHR (20 M, mean age = 18.5), 35 HC
(15 M, mean age = 17.77)
SIPS 3 T, EPI, GRAPPA parallel imaging
factor 2, 72 slices, 2x2x2mm
TBSS, ROI = SCP UHR vs. HC: No group differences in baseline SCPs.
Controls FA ↑ over 12 months, while UHR FA ↓ over
time.
Follow-up: 15UHR, 15 HC
Peters et al., [22] 10 UHR (mean age = 21.2), 10 EOS (mean
age = 21.6) and 10 HC (mean age = 21.1).
All male sample.
SIPS 3 T, EPI, 48 continuous
(para)transversal slices,
3x3.5x2.2 mm
Fiber tracking, ROIs = UF,
AF, CB, CC
No group differences
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Table 1 Diffusion tensor imaging studies on ultra-high risk samples (Continued)
Peters et al., [23] Same subjects as Peters et al. (2008) SIPS As above VBA, whole brain UHR vs. HC: FA ↓ bilateral superior and middle
frontal
EOS vs. HC: FA ↓ bilateral temporal & parietal, and
left frontal
Peters et al., [26] 10 UHR-N (mean age = 21.2), 7 UHR-P
(mean age = 22.6), 10 HC (mean age =
21.1). All male sample.
SIPS As above Fiber tracking, ROIs = UF,
AF, CB, CC
No group differences
Petersson-Yeo et al.,
[33]
19 (12 M) pairs EOS (mean age = 24.37)
vs. HC (mean age = 24.89)
CAARMS 3 T, EPI, 60 contiguous
axial 2.4 mm slices
TBSS, whole brain FA differentiated UHR and EOS from HC. Pattern of
findings were widely and diffusely spread, with no
clear concentration of regions.
FA did not differentiate UHR and EOS.19 (9 M) pairs UHR (mean age = 22.42)
vs. HC (mean age = 23.32)
15 (9 M) pairs UHR (mean age = 23.2)
vs. EOS (mean age = 23.2)
aDTI parameters: field strength, acquisition technique, slice number/thickness/direction, voxel dimensions AC-PC: anterior commissure - posterior commissure; AF = arcuate fasiculus; ATR = anterior thalamic radiation;
CAARMS: Comprehensive Assessment of At-Risk Mental States; CB = cingulate bundle; CC = corpus callosum; CST = cortiospinal tract; EOS = early onset schizophrenia; EPI: echo planar imaging; GRAPPA = generalized
autocalibrating partially parallel acquisitions; HC = healthy controls; IFOF = inferior fronto-occipital fasiculus; ILF = inferior longitudinal fasiculus; ROI = region of interest; SCP = Superior cerebellar peduncle; SCR = superior
corona radiata; SFOF = superior frontal occipital fasciculus; SIPS: Structured Interview for Prodromal Syndromes; SLF = superior longitudinal fasiculus; SOPS: Scale of Prodromal Symptoms; TBSS = tract based spatial statistics; UF
= uncinate fasiculus; UHR = ultra high risk for schizophrenia; UHR-P = ultra-high risk subjects who transitioned to psychosis; UHR-N = ultra-high risk subjects who did not transition to psychosis; UHR-NA = ultra-high risk subjects
who did not transition to psychosis and were prescribed antipsychotic mediation; UHR-NN = ultra-high risk subjects who did not transition to psychosis and were not prescribed antipsychotic mediation; VBA = voxel
based analyses
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of these UHR individuals go on to develop full-threshold
psychosis, others have resolution of symptoms and some
have persistent non-psychotic disorders (i.e. low-level
sub-threshold symptoms). Therefore, it is important to
look at longitudinal clinical and functional outcomes
within UHR populations.
Among the first of the few studies to prospectively fol-
low UHR subjects, Peters et al. [26] failed to identify any
baseline differences in FA for a priori defined white mat-
ter tracts [uncinate and arcuate fasciculi, anterior and
dorsal cingulate, and subdivisions of the corpus callo-
sum] in UHR subjects who transitioned to psychosis
(UHR-P, N = 7), those who did not transition to psych-
osis (UHR-N, N = 10), and healthy controls (N = 10).
However, it should be noted that the small sample size
in this study may have led to Type II error. In compari-
son, Karlsgodt et al.’s [27] region of interest study of 36
UHR subjects and 25 controls found lower baseline FA
in the UHR group within the superior longitudinal fasi-
culus. Cross-sectional analysis of age-effects revealed
that the UHR group did not exhibit the expected age-
related increase in FA within the medial temporal lobe.
Lower FA in the medial temporal lobe and inferior lon-
gitudinal fasiculus was also found to predict lower func-
tioning within the UHR group at 15-month follow-up.
Further, there was a trend towards lower FA in the med-
ial temporal lobe in UHR-P (17 %) compared to UHR-N
subjects.
Similarly, Mittal and colleagues’ [28] study of the
cerebellar-thalamic tract did not identify any significant
differences at baseline between UHR subjects (N = 33)
and controls (N = 35). However, 12-month follow-up of
a subset of participants [15 UHR, 15 controls] found
that UHR subjects exhibited a significant reduction in
FA over time compared to healthy controls, resulting in
significantly lower FA at follow-up. Although the study
did not examine transition to psychosis, they did find
that positive and negative symptoms declined over time
in UHR subjects. A subsequent study by the researchers
identified a similar group × time interaction within the
thalamic-hippocampal tract [29]. Specifically, UHR sub-
jects (N = 26) exhibited a significant reduction in FA
over time in comparison to healthy controls (N = 21).
This was driven by a pattern of increased FA in controls
over the 12-month follow-up period and reduced FA in
UHR subjects, although main effect of time was not sig-
nificant within either group.
Only three longitudinal studies have used a whole brain
approach to examine FA differences to date. The first of
these studies by Bloemen and colleagues [30] combined
baseline neuroimaging assessments with clinical follow-up
of UHR individuals at 24 months to ascertain transition to
psychosis. They identified lower baseline FA in UHR-P (N =
10) compared to controls (N= 10) in the medial frontal
lobes bilaterally, approximate to the left anterior thalamic ra-
diation and inferior fronto-occipital fasciculus. Lower FA
was also identified in white matter lateral to the right puta-
men and left superior temporal lobe in UHR-P compared to
UHR-N (N= 27) groups. Interestingly, the same group com-
parison identified higher FA in those who transitioned
within the left white matter of the medial temporal lobe. In
addition, positive symptoms were negatively correlated with
FA in the medial temporal lobe within those who transi-
tioned, and were also negatively correlated with FA in the
right superior temporal lobe within the overall UHR group.
Carletti et al. [31] were the first to investigate longitu-
dinal differences in white matter, having neuroimaging
follow-up of UHR subjects and healthy controls after
28 months, along with baseline scans of first episode
psychosis patients. They found that first episode patients
exhibited widespread reductions in FA, as well as in-
creased radial and axial diffusivities, compared to con-
trols at baseline. The UHR group was found to lie in
between these two groups on various DTI indices, in-
cluding within the parietal region, encompassing the
SLF, corpus callosum, and inferior fronto-occipital fas-
ciculus. However post-hoc analyses failed to identify any
significant differences between UHR and control groups.
Longitudinal follow-up revealed that UHR-P subjects
(N = 5) exhibited a progressive reduction in FA in left
frontal white matter, including the anterior limb of the in-
ternal capsule, corpus callosum, superior corona radiata
and superior frontal occipital fasciculus in comparison to
UHR-N subjects (N = 17). However, neither group exhib-
ited significant within-group change, nor were any signifi-
cant differences in comparison to controls reported. The
only other study to longitudinally examine white matter
changes identified significantly lowered FA within the cor-
pus callosum in UHR subjects compared to healthy con-
trols at baseline [32]. They were unable to examine
longitudinal FA change in UHR subjects who transitioned
compared to those who did not transition at 12-month
follow-up due to small sample size of the former group
(N = 4). However, they did identify a significant negative
correlation between change in positive symptoms and
change in FA within the same region in UHR-N subjects.
This effect remained significant after accounting for age,
sex and antipsychotic use. The authors argued that preser-
vation of white matter may therefore reduce the risk of
developing psychosis, thus acting as a protective neuro-
biological factor.
A recent study by Pettersson-Yeo et al. [33] used ma-
chine learning to examine the ability of structural mag-
netic resonance imaging (MRI) and functional magnetic
resonance imaging (fMRI), DTI, genetic and cognitive
data to differentiate between UHR, first episode patients
and healthy controls at the single-subject level. They
found that first episode patients were identifiable at the
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individual level using a range of biological and cognitive
measures. Specifically, the algorithm was able to accur-
ately classify first episode patients in comparison to con-
trols using genotype (68 %), DTI (66 %), fMRI (66 %) and
cognitive data (74 %). It was also able to differentiate first
episode and UHR patients using structural MRI (77 %),
fMRI (73 %) and cognitive data (67 %). In comparison,
only structural MRI and DTI discriminated UHR from
control participants, with an accuracy of 68 % and 66 %,
respectively. These findings support the notion that white
matter integrity is implicated prior to the onset of psych-
osis and is a sensitive measure of risk for transition.
Although limited in number, these studies provide
some evidence for lower FA and higher MD in UHR
subjects who transition to psychosis, relative to UHR in-
dividuals who do not transition, and healthy controls
(refer to Table 1 for an overview). While the exact pat-
tern of white matter differences is not consistent across
studies, frontal, fronto-temporal and fronto-limbic con-
nections, including the superior longitudinal and uncin-
ate fasiculus, cingulum, and corpus callosum appear to
be implicated. These findings in UHR samples suggest
that white matter abnormalities may play an important
role in the development of psychotic disorders, although
further longitudinal research is needed that examines
within-subject change in FA along with progression to
psychosis. In addition, the small sample size of many
studies to date, along with variations in DTI analytic
methods, may be partly responsible for the inconsisten-
cies in findings. Along this line, future meta-analyses
may have help clarify the exact location and nature of
white matter abnormalities in high-risk samples.
White matter and polyunsaturated fatty acids
There is evidence to suggest that the observed changes in
DTI indices of white matter integrity are due, at least in
part, to damage to the myelin sheath that insulates axons
and transmits electric signals between nerves in schizo-
phrenia patients [34, 35]. The myelin sheath is formed by
the membrane of oligodendrocytes and consists of ap-
proximately 70 % lipids, with phospholipids and choles-
terol accounting for the largest proportion of membrane
lipids in mammals [36, 37]. PUFAs are important compo-
nents of the phospholipid layers in all cell membranes, in-
cluding oligodendrocytes. Arachidonic acid (AA, C20:4n-
6), docosahexaenoic acid (DHA, C22:6n-3) and nervonic
acid (NA, C24:1n-9) are among the most important fatty
acids in the nervous system. They impact on neuronal
functioning through two main mechanisms. Firstly, they
play a role in maintaining membrane structure, and
modulating the function of membrane receptors, ion
channels and enzymes [38]. Secondly, they are a source of
precursors for eicosanoids, including prostaglandins,
thromboxanes and leukotrienes, which play an important
role in immune and inflammatory responses, and also act
as second messengers in intra- and inter-cellular signal
transduction [38].
PUFAs are acquired through dietary intake and the
amount of intake affects the rate of phospholipid synthe-
sis, which in turn impacts on the quantity and quality of
membrane phospholipids [39]. If PUFAs are not avail-
able during myelin synthesis, there is disruption result-
ing in amyelination or dysmyelination. Such myelin
changes have been identified in rats with PUFA defi-
ciency [40], and dietary supplementation of omega-3
fatty acids in rats has been found to simulate the expres-
sion of myelin proteins in the brain [41]. In humans,
dietary supplementation of PUFAs has been found to re-
duce the occurrence of white matter abnormalities in
the elderly [42], and the exacerbation rate and disability
in patients with multiple sclerosis [43]. Apart from diet-
ary intake, genetic factors also impact the synthesis of
PUFAs. The human-specific haplotype of fatty-acid desa-
turase (FADS) genes has been associated with decreased
blood levels of DHA and AA (suggestive of lower bio-
synthesis of PUFAs), as well as decreased white matter
development from childhood to adulthood [44].
Peters and colleagues [45] report the only study to
date examining the relationship between myelination
and PUFAs in healthy individuals using DTI. They inves-
tigated whether white matter integrity, using DTI ana-
lysis, was associated with blood levels of PUFA
concentrations and the activity of phospholipase A2 (the
main enzyme regulating membrane PUFA metabolism)
in 9 to 20 year olds. Interestingly, they found that lower
blood PUFA concentrations were related to higher FA in
the corticospinal tract, anterior thalamic radiation, infer-
ior fronto-occipital fasiculus and cingulum. In addition,
lower blood PUFA concentrations were related to lower
RD in the same regions, as well as the uncinate, superior
and inferior longitudinal fasiculi. The authors argue that
active white matter myelination during adolescence may
require more vigorous consumption of PUFAs from per-
ipheral membranes, given the continued white matter
changes that have been identified during this period
[46]. Hence while these findings highlight a relationship
between blood PUFA concentrations and DTI-indices of
white matter integrity, it remains uncertain whether the
same direction of association would be present following
this developmental period. There is a need for further
research across different ages, ideally using longitudinal
research to examine potential developmental effects and
better understand these complex associations.
Polyunsaturated fatty acids and white matter in
schizophrenia
Given the relationship between PUFAs and myelination,
we propose that white matter integrity may mediate the
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relationship between PUFAs and risk for schizophrenia.
There is a substantial body of evidence for lowered
blood PUFA concentrations in schizophrenia. These in-
clude reductions in blood levels of DHA, AA, NA, doco-
sapentaenoic acid (DPA) and linoleic acid (LA) in
patients [47–49], including medication-naïve patients
[50, 51]. Similar findings have also been identified in
postmortem studies [52]. Consistent with these findings,
there is evidence that omega-3 PUFA dietary supple-
mentation may prevent the transition from UHR to
psychosis, with Amminger et al.’s [53] placebo-
controlled clinical trial finding that 12 weeks of PUFA
supplementation reduced the risk of transition at 12-
months follow-up. In this study, omega-3 PUFAs also
significantly reduced positive, negative, and general
symptoms, and improved functioning at follow-up com-
pared to the placebo. A subsequent study found that
higher NA levels were significantly related to lower
negative and positive symptoms, as well as higher global
functioning in the same UHR sample at baseline [54].
However, AA and DHA levels did not exhibit any signifi-
cant associations with symptoms or functioning. They
also found that lower levels of NA predicted transition
to psychosis in individuals who received the placebo
(those who received the omega-3 PUFA supplementation
were excluded due to significant treatment effects on
transition). These findings remained after controlling for
variables known to influence fatty acid metabolism, includ-
ing age, cigarette smoking, cannabis use and antidepressant
use. Notably, the observation that supplementation with
omega-3 PUFAs may prevent transition to psychosis sug-
gests that omega-3 fatty acids may offset the risk conferred
by decreased levels of NA.
There is also preliminary DTI research specifically in-
vestigating the relationship between PUFA, white matter
integrity and schizophrenia. Peters et al.’s [55] study of
12 patients with recent-onset schizophrenia, identified a
significant positive correlation between total blood
PUFA concentration and FA in the uncinate fasciculus,
the white matter tract connecting the anterior temporal
lobe with the orbitofrontal lobe, using a region-of-
interest approach. A subsequent whole brain voxelwise
analysis of 30 male patients with recent-onset schizo-
phrenia found that lower total blood PUFA concentra-
tion was related to lower FA levels across the brain,
including the corpus callosum, and bilateral parietal, oc-
cipital, temporal and frontal regions [56]. This relation-
ship was primarily driven by AA concentration, and to a
lesser extent by NA, LA and DPA concentrations.
Greater severity of negative symptoms was also related
to lower FA and NA concentration. These findings pro-
vide support for the notion that white matter abnormal-
ities are related to PUFA levels in schizophrenia.
Although the exact mechanism remains uncertain, it has
been hypothesised that reduced PUFA levels may be re-
lated to lowered FA via inflammatory processes [56].
Specifically, AA can be transformed to proinflammatory
prostaglandins and leukotrienes after being released
from cell membranes, while omega-3 fatty acids can
transform to anti-inflammatory factors [57]. Thus in-
creased metabolism of omega-3 and −6 fatty acids, pos-
sible through altered immune function, may result in
white matter inflammation and consequently disrupted
myelination in schizophrenia. It is also possible that oxi-
dative stress may play a role, as reduced antioxidant en-
zymes and increased plasma lipid peroxides have been
related to lowered PUFA concentrations in first episode
and never-medicated patients [58]. Further research is
needed to fully unpack these potential mechanisms and
gain a better understanding of biological processes that
may be implicated in schizophrenia. We are currently con-
ducting a study funded by the National Health and Medical
Research Council Australia (NHMRC; APP1067040) to es-
tablish if membrane PUFA concentrations correlate with
reduced white matter (WM) integrity in UHR individuals.
This study investigates the clinical relevance of WM integ-
rity and PUFA interaction in relation to illness progression
in the prodromal phase of psychosis.
There are inconsistencies in the literature based on
these preliminary studies that need to be addressed.
Firstly, the direction of association is not consistent with
that identified in healthy adolescents [45]. As mentioned
above, these differences may relate to the age of samples,
and there is a need for more research examining poten-
tial development effects on the relationship between
blood PUFA concentration and white matter integrity in
healthy individuals. Furthermore, Peters et al.’s [56] find-
ings within the temporal lobe were reduced to trend
level effects when controlling for medication and dur-
ation of illness. Therefore, it would be valuable to exam-
ine the relationship between PUFA and white matter
integrity in UHR samples not confounded by such fac-
tors. It is also possible that different mechanisms under-
lie the relationship between blood PUFA concentrations
and white matter in healthy individuals and those with
schizophrenia, and future research comparing these two
groups in an age-matched sample may help us better
understand these differences and the potential neurobio-
logical processes underlying schizophrenia. There are
also inconsistencies in relation to the specific fatty acid
that may be implicated in the disease process, and asso-
ciations in PUFA alterations and symptoms may be spe-
cific to stage of illness [18]. For example, in UHR
individuals, NA was found to be associated with symp-
toms [54], while DTI research in individuals with recent
onset schizophrenia shows that AA (and to a lesser ex-
tent NA) is more strongly associated with fractional an-
isotropy [55]. Hence, certain PUFA alterations may be
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salient in the at-risk stage of illness, marking the poten-
tial to evolve into a psychotic disorder, without necessar-
ily having a direct and causal relationship with
schizophrenia [59]. This would explain why PUFA sup-
plementation may be of benefit to very early stages of
psychotic disorder (i.e., UHR individuals) and less bene-
ficial in patients with established schizophrenia [60].
Conclusions
There is much to be learnt about the biological underpin-
nings of the symptoms and deterioration of functioning
characteristic of UHR individuals, and the predictive value
of these markers for conversion to psychosis. There are
strong international research efforts currently aimed at ad-
dressing these issues [61–63], with the hopes of developing
predictive tools using imaging and other biological markers
to complement currently used clinical phenotypic criteria.
Specifically addressing the issue of PUFAs and white
matter integrity in UHR is the Myelin Integrity Neuro-
imaging (MINT) study at Orygen - The National Centre
of Excellence in Youth Mental Health, Australia. This is
the first study to combine neuroimaging and blood-
based assessments with longitudinal clinical assessments,
which will allow examination of the interaction between
PUFA and white matter prior to the onset of schizophre-
nia. In addition, the project will examine the role of
PUFAs and white matter integrity in disease progression
(i.e., transition to psychosis, poorer functional outcomes)
in UHR patients. It will provide us with new insight into
the pathophysiology of psychosis, which will help us bet-
ter understand the effectiveness of interventions altering
cell membrane lipids and potentially provide the basis
for development of novel treatments. Together with
other cutting-edge research in this area, this study will
also ultimately aid in predicting which UHR subjects will
actually transition to psychosis, and their likely func-
tional and symptomatic outcomes.
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